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Abstract: It was evaluated the Brazilian panorama regarding the registration and use of phytotherapics. A descriptive study about herbal 
medicines was carried out using the Pubmed and Portal Capes databases, and online data from the National Health Surveillance Agency 
(ANVISA). Of the 114-plant species described in the list of Brazilian Common Denomination (CBD), 67 have at least one formulation 
registered by ANVISA, with emphasis on Ginkgo biloba L. Fifteen different pharmaceutical forms were observed, the most common being 
tablets. There are 22 different indications, laxative was the most cited. Publications in the field of herbal medicine have increased 
significantly in the last 2 decades. 
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Resumen: Se evaluó el panorama brasileño sobre el registro y uso de fitoterápicos. Se realizó un estudio descriptivo de las hierbas 
medicinales utilizando las bases de datos Pubmed y Portal Capes, así como datos en línea de la Agencia Nacional de Vigilancia Sanitaria 
(ANVISA). De las 114 especies de plantas descritas en la lista de Denominación Común Brasileña (CBD), 67 tienen al menos una 
formulación registrada por ANVISA, con énfasis en Ginkgo biloba L. Se observaron 15 formas farmacéuticas diferentes, siendo las más 
comunes las tabletas. Hay 22 indicaciones diferentes, laxante fue el más citado. Las publicaciones en el campo de la medicina herbal han 
aumentado significativamente en las últimas 2 décadas. 
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INTRODUCTION 
Along the humanity evolution the interest for the 
research of medicinal plants has increased, in this 
context, emerges the phytotherapy that can be defined 
as the study of plants and its application on the cure 
of diseases (VENTURA, 2012). 
The Brazilian biome is a vast field, still little 
valued, for research in the area of natural products. 
Researches in this area related that several plants 
show important pharmacological activity such anti-
inflammatory, antioxidant, antitumor, among others, 
which corroborates to the encouragement of use of 
phytotherapy and research in this area (VENTURA, 
2012). To get an idea of plants potential on the 
development of new drugs, between 1983 and 1994 
the FDA approved 520 new drugs, these, 196 were of 
natural origin (DAVID et al., 2004). 
According to Resolution No. 26 of May 13, 
2014, which regulates the registration of herbal 
medicines and the registration and notification of 
traditional herbal products, the herbal product is that 
used for prophylactic, curative or palliative purposes 
obtained exclusively of vegetal raw material, not 
considering those with isolated active substances 
although they have vegetal origin. In this resolution, 
the National Agency of Sanitary Surveillance 
(ANVISA) defines two new terms used in 
phytotherapy, herbal medicine and traditional herbal 
product (BRASIL, 2014a). 
Since the 1970s, the World Health 
Organization (WHO), with the creation of the 
Traditional Medicine Program (which includes 
phytotherapy, homeopathy, traditional Chinese 
medicine/acupuncture and anthroposophic medicine) 
has started to encourage the preservation of the 
culture of several populations, linking the popular 
knowledge to medicine, thus promoting other forms 
of care (WHO, 2002).  
In Brazil, the ANVISA (National Health 
Surveillance Agency), according to Law 9782/1999, 
which defines the National Health Surveillance 
System and creates the National Sanitary 
Surveillance Agency, is responsible for regulating, 
recording and monitoring the marketing of these 
products at the national level (BRASIL, 1999). 
Currently many Laws govern the use of herbal 
medicines in Brazil. The RDC No 26 of 2014 is the 
current resolution and provides about the registration 
of herbal medicines and the registration and 
notification of traditional herbal products (BRASIL, 
2014a). Other Laws, such as, Law No 5991 of 1973, 
provides about the Sanitary Control of the Trade of 
Drugs, Medicines, Pharmaceutical Supplies and 
Related, which legally bases the control of these 
medicines (BRASIL, 1973). 
There are countries that accept herbal 
medicines with several compounds, provided they 
have a good clinical response. Signaling a change of 
attitude for the recognition of these drugs, provided 
that they have a good clinical observation. This 
chance is linked to the understanding that the human 
body is a complex organism and that few diseases 
can be attributed to a single cause. The Ministry of 
Health, when recommending and indicating 66 
medicinal plants approved by ANVISA, whose use is 
consecrated in the culture of Brazilian popular 
medicine, had a correct and coherent attitude. The 
next step is to supervise the commercialization of 
these herbal medicines to preserve the health of the 
consumer. 
Between 2011 and 2014, the 
phytotherapeutics segment grew by 20% in the 
number of units sold and 24% in sales, a result that is 
very positive considering the scenario of the global 
economy (IMS Health apud VALÉCIO, 2015). 
In 2006, the herbal industry in Brazil 
accounted for 4% of the pharmaceutical industries 
present in the country (171 phytotherapeutic 
laboratories were responsible for marketing 727 
registered products/medicines), of which 50% were 
in the Southeast region and 10% in the South region 
of the country. The North region that is known for its 
biodiversity in fauna and flora presented only 2% of 
these industries (HASENCLEVER et al., 2009). In 
addition, it is a very concentrated market, in 2007, 
only 20 laboratories were responsible for the sale of 
84.70% of the total segment, accounting for 67.44% 
of total sales. The most representative laboratories in 
that year were Altana Pharma (German origin), 
Farmasa (national capital) and Marjan Farma 
(national) (FREITAS, 2007). It is observed, in this 
scenario, the need for the development of the 
phytotherapeutic drug industry, together with 
research in this area (YUNES et al., 2001). ABIFISA 
has its contribution in Brazil as an organ that is active 
in the defense of collective and individual interests in 
this segment. 
Based on the importance and growth of this 
science worldwise and in Brazil, the aim of this 
article was to carry out a survey of the legislation that 
covers phytotherapics, the herbal medicines that are 
registered in our country, the evolution of the number 
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of published studies involving the theme and the 
billing of this sector. 
 
METHODOLOGY 
It is a descriptive study that evaluated the use and 
record of herbal medicines in Brazil. A research was 
carried out based on secondary data obtained from 
DATAVISA (ANVISA website – BRASIL, 2016a), 
taking into account the name of the plant species 
used, its pharmaceutical form and its therapeutic 
indication. The medicinal plants described in the list 
of Common Brazilian Denominations (DCB) present 
in RDC No. 64 of December 28, 2012 (BRASIL, 
2013) and updated by RDC No. 38, of August 26, 
2015, were searched (BRASIL, 2015a). 
A survey was also carried out in Portal Capes 
using some descriptors as “phytotherapy”, “herbal 
medicine”, “phythoterapic”, “legislation” to obtain 
information about the evolution in the use of herbal 
medicines by the population, the sector growth, the 
current legislations involving this theme, the use of 
these drugs in the single health system. 
A survey was carried out in the Pubmed 
database with the only the descriptor "phytotherapy", 
and with the descriptors "phytotherapy" AND 
"Brazil", in order to verify the evolution of the 
number of publications in this area worldwide and 
local (Brazil), were considered the first articles 
published (1947 and 1969, respectively) to the most 
recent, published until January 2017. In addition, 
some of the best-selling herbal medicines in the year 
2014 come from the international pharmaceutical 
marketing consultant IMS Health do Brasil. 
Based on the survey conducted by 
DATAVISA and articles published from 1969 to 
January 2017, it was possible to evaluate the 
evolution of the topic in Brazil. 
 
RESULTS AND DISCUSSION 
Legislation 
The Laws have always been important guides in the 
formation of the society. They help the organization 
by establishing order before a population. In Brazil, 
when it comes to health, we have a well-founded 
legislation and are guided mainly by ANVISA and 
the Ministry of Health (MS). In the case of herbal 
medicines can be cited as important laws that 
establish the control and registration of this type of 
product and which provide information about its 
potential use. 
In the 1970s, laws such as Law No. 5991 of 
1973, which established the Sanitary Control of the 
Trade in Drugs, Medicines, Pharmaceutical Supplies 
and Related Products were drawn up, and provided 
other provisions, which included important concepts 
in the scope of Phytotherapy (BRASIL, 1973). 
The National Policy of Medicinal Plants and 
Phytotherapy (PNPMF) (BRASIL, 2006a) should be 
mentioned, and within Unified Health System (SUS) 
the National List of Essential Medicines (RENAME), 
the Document No. 31 of Primary Care and the 
National Policy on Integrative Practices (PNPIC) 
(BRASIL, 2012b), summarize in their texts the 
importance of valuing traditional knowledge, 
stimulating knowledge and research in the field of 
alternative medicine and rational use in the field of 
phytotherapy. 
In this context, the RDC No. 26 of 2014 
deserves to be highlighted, since it is the current 
resolution dealing with the registration of herbal 
medicines, registration and notification of traditional 
herbal products. In addition, it brings important 
definitions such as Phytotherapeutic and Traditional 
Phytotherapeutic Product, which changed after its 
publication several drug registration processes in our 
country and created a new class of products. 
According to this RDC, herbal medicine is that 
"obtained by the use of plant raw materials that have 
safety and efficacy based on clinical studies". 
Traditional herbal product is defined as being 
"obtained from plant raw materials, its safety and 
effectiveness being based on data of safe and 
effective use described in technical-scientific 
literature and can be used without supervision" 
(BRASIL, 2014a). 
The publication of RDC 26/2014 had an 
impact on the industry because it changed the register 
of herbal medicines. In addition to including the term 
traditional herbal product, it establishes that for the 
registration of both classes (herbal medicines and 
traditional phytotherapeutic products) some 
adjustments are made, leading the industry to adapt to 
the new Resolution. 
At the moment to register these products it is 
necessary that the applicant requires to the Brazilian 
Pharmacopoeia the inclusion of the constituents of 
the phytotherapic in the list of the DCB, if these are 
not already in the same one. The technical report, 
stability study report, production and quality control 
report, plant drug analysis report, the finished product 
analysis report, safety and efficacy/effectiveness 
reports are requested as mandatory documents. 
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It is clear from the mandatory records, legal 
basis and definitions present in these resolutions, that 
phytotherapy in Brazil is a subject that has been 
taking on importance in recent years. With well-
established guidelines and laws related to the subject, 
which stimulate the research and development of this 
sector, besides stimulating the adoption of herbal 
medicine in the public health system. The chemistry 
of natural products is the oldest studied in Brazil, in 
addition, the country has a vast biome still to be 
researched, this scenario contributes to research in 
this sense and the Laws, guidelines and regulations 
are indispensable in this scenario. 
Having strict legislation that guides the 
processes of development, production, quality control 
and inspection of these products is of extreme 
importance to ensure that the products that are on the 
market are effective and safe, and consequently, 
stimulate the prescription of them, with consequent 
increase in consumption and market growth. 
 
Use of phytoterapics in the Brazilian Health System 
(SUS) 
The insertion of herbal medicines into basic health 
care in the outcome of a struggle that precedes the 
creation of the Unified Health System (SUS), 
regulated by Law 8080 of 1990, several health 
professionals contributed fundamentally to the 
creation of policies that allowed the inclusion of this 
therapy in public health services in Brazil (BRASIL, 
2006a). 
In 2006, the publication of two policies was 
instrumental in guiding legislation, programs and 
projects that allowed the development of strategic 
lines that strengthened the use and access to 
medicinal plants and herbal medicines in primary 
health care. By means of Ordinance No. 971, of May 
3, 2006, the National Policy for Integrative and 
Complementary Practices in the SUS (PNPIC) was 
created, which contemplates Phytotherapy as a 
therapeutic option. In the same year, the National 
Policy of Medicinal Plants and Phytotherapy 
(PNPMF) was established by decree No. 5.813, of 
June 22, 2006, with the objective of providing safe 
access and rational use of medicinal plants and 
phytotherapics In our country (BRASIL, 2006b, 
2006c). 
In this way, the Ministry of Health, in order 
to contribute with the expansion of alternative 
therapies, allows the inclusion of some 
phytotherapics from 2007 in the National Relation of 
Essential Medicines (RENAME), integrating the 
Basic Component of Pharmaceutical Assistance, 
which was being improved over the years (BRASIL, 
2007). 
In 2007, two phytotherapics were included in 
the basic component of Pharmaceutical Assistance: 
Mikania glomerata (Guaco) e o Maytenus ilicifolia 
(Espinheira Santa) (Brasil, 2007). In 2009, six herbal 
medicines were added to the National List of 
Medicines and Complementary Supplies for 
Pharmaceutical Care in Primary Care, totaling a list 
of eight herbal medicines due to the inclusion of 
Cynara scolymus (artichoke), Schinus 
terebenthifolius (aroeira), Rhamnus purshiana 
(cascara sagrada), Harpagophytum procumbens 
(devil's claw), Glycine max (soy isoflavone) and 
Uncaria tomentosa (cat's claw) (BRASIL, 2009). In 
2012, four new drugs, Aloe vera (aloe vera), Mentha 
piperita L. (peppermint), Plantago ovata Forssk 
(plantago) and Salix alba L. (willow), were added in 
this list, totaling 12 herbal medicines listed in 
RENAME (BRASIL, 2012a). 
Currently, there are 12 phytotherapics that 
make up the cast established in RENAME, and it did 
not present any changes since 2012 (Table 1) 
(BRASIL, 2015). 
The availability of phytotherapics to SUS 
patients, regulated through public policies, allows 
these patients another treatment option, besides 
favoring popular participation, by rescuing the 
knowledge acquired by the population (Figueredo et 
al., 2014). 
However, some difficulties and challenges 
can be observed in the attempt to implant 
phytotherapeutic programs, such as doubts and 
knowledge about the efficacy and safety of treatment 
by health professionals, which favors the use of 
synthetic medicines, the need for adequate physical 
structure, and acceptance of the professionals 
involved (Araújo et al., 2014; Figueredo et al., 2014). 
In the search for improvements, the Ministry 
of Health directed financial resources, around R$ 3.4 
million, to be applied in projects approved by means 
of public notice. With the objective of supporting and 
strengthening the structuring of primary care through 
the availability of herbal medicines, the purchase of 
inputs, hiring and training of professionals, in 
addition to enabling the purchase of necessary 
equipment. The investments aim to strengthen 
projects, which make it possible to increase the 
supply of herbal medicines in the SUS. Some of the 
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selected projects were in cities of the states of Rio de 
Janeiro, Minas Gerais, São Paulo, Paraná and Rio 
Grande do Sul (BRASIL, 2016b). Thus, it can be 
noticed an expansion in investments in this sector by 
the Ministry of Health and in an attempt to expand 
the number of herbal medicines supplied to the 
Brazilian population by the single health system. 
However, there is a need to increase the list's list of 
RENAME, which since 2012 remains stagnant. 
 
TABLE 1 – PHYTOTHERAPY PRESENT AT RENAME 2014 
Generic designation 
Brazilian Common 
Name 
  (DCB) 
Indication/Action 
Pharmaceutical Form/ 
Description 
Artichoke 
 
Cynara scolymus L. 
Treatment of symptoms of functional 
dyspepsia (postprandial discomfort syndrome) 
and mild to moderate hypercholesterolemia. It 
presents collagenous and choleretic action. 
Capsule, tablet, dragee, 
oral solution and/or 
tincture 
Aroeira 
 
Schinus terebinthifolius 
Raddi 
It presents healing, anti-inflammatory and 
topical antiseptic action for gynecological use 
Gel and/or ovule 
Aloe Vera 
 
Aloe vera (L.) Burm. f. 
Topical treatment of 1st and 2nd degree burns 
and as a coadjuvant in cases of psoriasis 
vulgaris 
Cream 
Cascara sagrada 
 
Rhamnus purshiana 
DC. 
Supporting in cases of eventual intestinal 
constipation 
Capsule and/or tincture 
Espinheira Santa 
 
Maytenus officinalis 
Mabb. 
Coadjuvant in the treatment of gastroduodenal 
gastritis, ulcer and symptoms of dyspepsia 
Capsule, emulsion, oral 
solution and/or tincture 
Devil's claw 
Harpagophytum 
procumbens 
Treatment of acute low back pain and as a 
coadjuvant in cases of osteoarthritis. It has 
anti-inflammatory action 
Capsule or tablet 
Guaco 
 
Mikania glomerata 
Spreng. 
It has expectorant and bronchodilator action 
Capsule, oral solution, 
tincture and/or syrup 
Peppermint 
 
Mentha x piperita L. 
Treatment of irritable bowel syndrome. 
Antiflatulent and antispasmodic action 
Capsule 
Soy isoflavone 
 
Glycine max (L.) Merr. Supporting the relief of climacteric symptoms Capsule or tablet 
Plantago 
 
(Plantago ovata 
Forssk.) 
Supporting in cases of habitual intestinal 
constipation. Treatment of Irritable Bowel 
Syndrome 
Powder for oral 
dispersion 
Willow 
 
(Salix alba L.) 
Treatment of acute low back pain. It has anti-
inflammatory action 
Tablet 
Cat's claw 
 
Uncaria tomentosa 
(Willd. ex Roem. & 
Schult.) DC. 
Supporting in cases of arthritis and 
osteoarthritis. It has anti-inflammatory and 
immunomodulatory action 
Capsule, tablet and/or gel 
SOURCE: BRASIL (2015) 
 
The availability of phytotherapics to SUS 
patients, regulated through public policies, allows 
these patients another treatment option, besides 
favoring popular participation, by rescuing the 
knowledge acquired by the population (Figueredo et 
al., 2014). 
However, some difficulties and challenges 
can be observed in the attempt to implant 
phytotherapeutic programs, such as doubts and 
knowledge about the efficacy and safety of treatment 
by health professionals, which favors the use of 
synthetic medicines, the need for adequate physical 
structure, and acceptance of the professionals 
involved (Araújo et al., 2014; Figueredo et al., 2014). 
In the search for improvements, the Ministry 
of Health directed financial resources, around R$ 3.4 
million, to be applied in projects approved by means 
of public notice. With the objective of supporting and 
strengthening the structuring of primary care through 
the availability of herbal medicines, the purchase of 
inputs, hiring and training of professionals, in 
addition to enabling the purchase of necessary 
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equipment. The investments aim to strengthen 
projects, which make it possible to increase the 
supply of herbal medicines in the SUS. Some of the 
selected projects were in cities of the states of Rio de 
Janeiro, Minas Gerais, São Paulo, Paraná and Rio 
Grande do Sul (BRASIL, 2016b). Thus, it can be 
noticed an expansion in investments in this sector by 
the Ministry of Health and in an attempt to expand 
the number of herbal medicines supplied to the 
Brazilian population by the single health system. 
However, there is a need to increase the list's list of 
RENAME, which since 2012 remains stagnant. 
 
Panorama of the registry of phytoterapics: datavisa 
data  
The registration of herbal medicines acts as an 
instrument by which the Ministry of Health 
determines its registration with the competent body, 
so that criteria related to the efficacy, safety and 
quality of these products are met, so that they can be 
commercialized (BRASIL, 2014a). 
With regard to registration of these products, 
according to RDC No. 26 of 2014, the herbal 
medicinal product may be of common or simplified 
registration. While the traditional herbal product can 
be a common, simplified or just notified, where prior 
communication is required to ANVISA "informing 
that it is intended to manufacture, import and/or 
commercialize traditional herbal products." Details 
regarding the registration of these products are 
presented in Table 2. 
 
TABLE 2 - REGISTRATION OF PHYTOTHERAPY PRODUCTS 
CATEGORY SAFETY AND EFFECTIVENESS / EFFECTIVENESS 
Herbal medicine 
Common 
Registry 
Presentation of clinical and non-clinical data demonstrating 
safety and efficacy. 
Simplified 
Registry 
a) Presence in the List of herbal medicines of simplified 
registration, according to Normative Instruction (IN) No. 2, of 
May 13, 2014; or 
b) Presence in well-established use monographs of 
phytomedicines of the European Community. 
Traditional Herbal 
Product 
Notified 
 
For the products listed in the Pharmacotherapeutic Form of the 
Brazilian Pharmacopoeia and that have a specific monograph of 
quality control published in pharmacopoeia recognized by 
ANVISA. 
Registry  
Proof of safe and effective use for a minimum period of 30 
years; Or by simplified registration. 
Simplified 
Registry 
 
a) Presence in the List of herbal medicines of simplified 
registration, according to Normative Instruction (IN) No. 2, of 
May 13, 2014; or 
b) Presence in well-established use monographs of 
phytomedicines of the European Community. 
SOURCE: BRASIL (2014a) 
 
The resolution also emphasizes the list of 
plants present in Normative Instruction (IN) No. 2 of 
2014, which lists plants recognized as safe and 
effective as being of simplified registration. Being 
indicated 27 plants used in the manufacture of 
phytotherapic medicines and 16 plants for the 
production of traditional herbal products. In total, IN 
lists 43 plants that can be commonly used in the 
production of herbal medicines without the need for 
additional evidence of efficacy and safety (BRASIL, 
2014b). 
These standards are valid only for 
industrialized products, and no registration or 
notification is required for preparations developed by 
traditional communities that are non-profit making 
and non-industrialized (BRASIL, 2014a). 
Such registration regulations allow Brazil to 
have a market with products developed through 
current standards, making it more attractive and 
promising nationally and internationally, while not 
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ignoring the traditional knowledge related to culture 
in using products of natural origin. 
The list of medicinal plants described in the 
DCB has 114 plant species, of which 67 species have 
at least 1 active registration in DATAVISA (an 
online consultation tool provided by ANVISA in 
order to provide information on processes, products 
and companies subject to health regulation). Of the 
47-remaining species, 25 of them do not present any 
results regarding the presence of registered 
formulations when they are researched and the 
remaining (22) have already been registered at some 
time, but currently there is no registered formulation 
for these medicinal plants. 
According to Normative Ruling No. 2 of May 
13, 2014, 25 of the species present in the list of DCB 
(21.93% of the total) are classified as herbal medicine 
of simplified registration and another 15 species of 
the same list are defined as Traditional Phytotherapic 
product of simplified registration (13.16% of the 
total), these do not need of additional safety and 
efficacy data (BRASIL, 2013). 
Based on this survey conducted in 
DATAVISA in May 2016, taking into consideration 
which formulations have a registration still valid, that 
is, with a registration deadline equal to or greater than 
May 2016, a total of 1.415 formulations were 
obtained with active registration by ANVISA in 
Brazil, 81.48% of the formulations are classified as 
simple (obtained from a single plant species), the 
others, 18.52% are defined as composite formulations 
(they have on your composition more than one plant 
species). 
Among the plant species with the highest 
number of phytotherapics registered are: ginkgo - 
Ginkgo biloba L. (10.53% of the total), the guaco - 
Mikania glomerata Spreng. (7.52% of the total), the 
valerian - Valeriana officinalis L (7.14%), the senna - 
Senna alexandrina Mill. (6.22% of the total), the 
Indian chestnut - Aesculus hippocastanum L. 
(5.35%), the artichoke - Cynara scolymus L. (5.65% 
of the total), the Santa - Maytenus ilicifolia Mart. ex 
Reiss (4.52%), the thistle-marian - Silybum marianum 
(L.) Gaertn. (3.67% of the total), ivy - Hedera helix 
L. (3.39%) and plantago - Plantago psyllium L. 
(3.25%).  Some of them, such as the ivy (Hedera 
helix L.), the senna (Senna alexandrina Mill.) and the 
ginko (Ginkgo biloba L.) are also among the best-
selling medicines in the country in 2014 (TABLE 3). 
As for the pharmaceutical form, there were 
15 varieties (Graphic 1), and the three most common 
pharmaceutical forms were the presentations of tablet 
(34.09%), gelatinous capsule (33.30%) and syrup 
(10.17%), these representing more than half of the 
registered formulations (77.49%). The remainder 
(22.51%) corresponds to the pharmaceutical forms of 
oral jelly, oral solution, effervescent powder, oral 
suspension, granules, gel, dragea, cream, ointment, 
elixir, tincture and oral emulsion.  More than half 
(72.48%) of the analyzed pharmaceutical forms are 
solid, 19.20% are liquid and 8.32% are semi-solid. 
The pharmaceutical presentation is intimately linked 
with the time and manner in which the product will 
be absorbed by the organism, and the correct choice 
depends on the study of each plant raw material, its 
chemical composition and the intended effect.
  
 
Graphic 1 
Pharmaceutical form of the phytoherapics registred in the anvisa 
 
Rech et al.  Brazilian panorama about the registration and use of herbal medicines 
 
 
Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/563 
 
 
Regarding the use for which they were 
defined during ANVISA registration, 22 different 
indications of use were observed (Table 3). The most 
common being: laxative (13.64% of the total), 
anxiolytic, anti-inflammatory, antivaricose and 
psychoanaleptic (all representing 7.57% of the total), 
and, expectorant, cholagogue and choleretic (both 
accounting for 6.06% of the total), these 
classifications represent 56.04% of the indications 
described. It can also be observed that among the 
most commercialized herbal medicines (Table 4), 
there are medicines indicated as laxative, anxiolytic, 
expectorant and cholagogue. 
 
 
 
 
 
Table 3 
Pharmaceutical indications suggested during the registration of phytotherapic in ANVISA 
 
PHARMACEUTICAL INDICATION TOTAL (%) 
Laxative 
Antivirose 
Psychoanalytical 
Antinflammatory 
Anxiolytic 
Cholagogue and choleretic 
Expectorant 
Aide in the treatment of the climacteric 
Healing 
Analgesic 
Digestive tract 
Hepatoprotective 
Antispasmodic 
Antiinfection / immunomodulatory 
Cerebral vasodilator 
Urinary tract infection 
Simple androgen 
Gynecology and obstetrics 
Antiemetic and antinauseant 
Immunostimulant 
Diuretic 
Iodine therapy 
Antidepressant 
Antacids and simple anti-ulcer 
Antilipemic 
Anti-phlogistic and anti-pruritic 
Cardiovascular apparatus 
Stimulating appetite 
 
13.64% 
7.57% 
7.57% 
7.57% 
7.57% 
6.06% 
6.06% 
4.54% 
4.54% 
3.03% 
3.03% 
3.03% 
3.03% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
1.51% 
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Publications about the phytotherapy theme 
When searching the publications about phytotherapy 
in the Pubmed database, 34538 articles were initially 
found when using only the descriptor "phytotherapy". 
Among the main subjects related to these descriptors 
are the adverse effects associated with it, its history, 
its efficacy, use, research, phytotoxicity, among 
others. When the descriptor "Brazil" was included in 
this research ("phytotherapy AND" Brazil), 1139 
articles were found, a small part of this total (3.29% 
of the articles obtained in the first moment) but that 
has been growing over the years, as observed in 
Graphic 2. Among the main themes of these 
publications can be mentioned the in vitro and in vivo 
biological activities of plants, ethnobotanical studies 
and chemical composition of plant extracts. 
 
 
 
Graphic 2 
Number of publications in function of the year 
 
When comparing the publications using the 2 
descriptors as a function of time, it is observed that 
the first published article that contains the descriptor 
"phytotherapy" was published in the year 1947 (1 
article) (according to Graphic 2) referring to the use 
of medicinal herbs Asteraceae family in the treatment 
of epilepsy, published in the “Australasian Journal of 
Pharmacy”. In the 1940s there was an increase in the 
number of studies involving epilepsy, and in the year 
1947 another 306 studies on this topic were 
published. The article refers to the traditional use of 
plants of this family in the treatment of this 
pathology. 
Some historical events have aided in the 
growth of studies and researches in the segment of 
medicinal plants, accompanying the increase of 
publications at world and national level. 
 Publications began to increase in the 1970s, 
from 1966 to 1976, 1,306 articles were published 
(3.78% of the total published), many of them are 
clinical studies involving herbal medicines, their 
application in the treatment of specific diseases. One 
of the milestones of this period was the creation of 
the Traditional Medicine Program by the WHO, as an 
alternative practice of health care. Some years later, 
in 1978, Alma Ata was declared a landmark for 
phytotherapy in a period when the world began to 
worry about the use of alternative practices for 
treatment and maintenance of health (WHO, 1978). 
However, in the 1980s, the discovery of new 
drugs based on their mechanism of action and 
molecular modeling (through the use of softwares), 
made the substances of synthetic origin more 
exploited, and that studies with medicinal plants in 
the background (Argenta et al., 2011).  
There is a considerable increase in 
publications on phytotherapy in the world in 1995 
(121 articles), in addition to studies related to the 
efficacy of these products, studies have been 
published regarding their safety. In addition to the 
development and growth of the pharmaceutical 
industry in the 1990s, in the period from 2002 to 
2005 the WHO again stimulated the use of traditional 
medicine and complementary medicine (Argenta et 
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al., 2011). In the period between 1981 and 2006, 50% 
of the drugs approved by the FDA were directly or 
indirectly derived from natural products (Ferreira & 
Pinto, 2010). An expansion is observed in subsequent 
years, with a greater number of publications in 2012, 
2318 articles were published (6.61% of the total), that 
is, almost double the number of articles published in 
10 years between 1966 and 1976 (Anti-oxidant, 
antimicrobial, anti-fungal, anti-tumor) in vitro and in 
vivo, identification of chemical substances from 
plants, evaluation of its clinical efficacy. The last 20 
years were responsible for 89.32% of the articles 
published so far in this area. One of the justifications 
for this fact is due to changes in medicine in the 21st 
century, which incorporates the principle of 
sustainable development, being associated with the 
concepts of preservation, care and traceability, 
making the idea of medicine associated with products 
of natural origin Resurgence and consequently there 
is an increase in the prescription of herbal products 
(Regis, 2014). 
As for the Brazilian scenario, the first article 
found dates from 1969 (1 article), a year in which 
there is an increase in world publications. This 
publication depicts the use of hallucinogenic 
substances of natural origin, citing the use of some of 
these plants by Brazilian indigenous tribes. In this 
period in Brazil, public investments in medicinal 
plants began, which occurred through the Medicines 
Center (CEME), instituted by Decree No. 
68806/1971. From the CEME the creation of some 
programs was important, such as the Program of 
Research of Medicinal Plants, whose objective was to 
develop research on plants present in Brazil (Brasil, 
1971; Oliveira, 1997). Prior to the establishment of 
the CEME in the late 1970s, WHO created programs 
to stimulate and encourage the rational use of 
traditional and complementary medicine, and to 
publish documents such as the WHO Strategy on 
Traditional Medicine 2002-2005, reaffirming the 
interest in the development of these practices that 
include phytotherapy. 
The publications became more expressive 
from the year 2001, with 23 publications (2.02% of 
the total), which mainly discuss the in vivo and in 
vitro use of medicinal plant species. In the same 
direction as the increase in national publications, in 
Brazil some National Health Conferences such as the 
12th, which occurred in 2003, enable and stimulate 
the production of medicines obtained from the 
national flora in order to expand the scenario of 
phytotherapy in Brazil. 
The expansion of studies on herbal medicines 
that we can observe from 2007 onwards is in line 
with its recognition in SUS in 2006, a period in 
which policies and guidelines are published that 
reinforce the great importance of medicinal plants by 
stimulating the use of natural resources. 
Over the years, it has been noticed that the 
advances obtained in the field of herbal medicines in 
our country are closely related to the achievements 
obtained for these products in the public system, the 
SUS, since from the 80's and after the creation of the 
SUS through Of the Federal Constitution, it is clear 
the institutionalization of phytotherapics as well as 
the autonomy of research developed in the area. 
Similar to that observed in world 
publications, publications involving phytotherapy in 
Brazil reached their peak in 2012, with 95 published 
articles (8.34% of the total, close to the number 
observed in the world scenario). In the last 2 decades, 
84.64% of the articles on phytotherapy have been 
published in Brazil, showing the same tendency 
observed for the world scenario in relation to the 
growth in the number of studies involving 
phytotherapy. 
These studies point to the expansion and 
interest in scientific research and in studies on 
medicinal plants in Brazil and in the world, mainly 
regarding the biological activities of several plant 
species. This shows a growth in research groups in 
this area, and an increasing interest in discovering the 
properties of medicinal plants and exploiting them, in 
order to make possible its application in an efficient 
and safe way, which makes it extremely important to 
Conducting clinical trials with these plants. Thus, 
phytotherapy and the study of medicinal plants are 
considered a promising field in scientific research. 
 
Analysis of the growth of the phytotherapic market 
in Brazil 
The Brazilian market currently markets several herbal 
medicines, which in turn gain the preference of 
patients and the population for being an alternative to 
the use of allopathic drugs, less aggressive and with 
fewer adverse effects than synthetics, in order to 
contribute to growth in Sales of these products 
(David et al., 2004). 
The great biodiversity present in our country, 
which corresponds to around 15 to 20% of the world 
total, with approximately 60000 listed higher vegetal 
species, and the popular knowledge about the vegetal 
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species, that contributes to the expansion of this 
Sector, which even in times of economic instability in 
the country, present good growth prospects (Brasil, 
2006). 
According to the International Federation of 
the Pharmaceutical Industry (Valécio, 2015), the 
Brazilian pharmaceutical industry has increased its 
sales of medicines over the past years, six times 
higher than the performance of developed markets. 
Herbal medicines contribute significantly to 
the drug market. The growth of this sector is around 
10% per year, and in 2001, it is estimated to have 
reached US $ 550 million (Knapp, 2001; Brazil, 
2006). The industry moves worldwide $ 21.7 billion 
per year. Carvalho et al. (2008) presented an estimate 
of Brazil's participation in the phytotherapic sector, 
which would reach US$ 160 million per year, moving 
annually around R$ 1 billion in its production chain. 
It is estimated that 10% of Brazilians 
consume some type of herbal medicine.  
In the year 2013, the main public responsible for 
consuming these products was composed of women 
over the age of 35 and working outside (Instituto 
Simone Terra apud Valécio, 2015). The category of 
herbal medicines available for sale in pharmacies in 
Brazil is wide. From a survey of the 10 most herbal 
medicines sold in Brazil in 2014 according to IMS 
Health (Table 4), some of these are also among the 
herbal products with the highest number of records 
according to data from DATAVISA, as is the case of 
ivy (Hedera helix L), senna (Senna alexandrina 
Mill.), and ginkgo (Ginkgo biloba L.).  
In a complementary way, it can be observed 
that other phytotherapics listed as the most sold 
(Table 4) have a therapeutic classification that is 
similar to the most frequent indications suggested 
during the registration of herbal medicines in 
ANVISA (Table 3), among them, laxative, anxiolytic, 
expectorant and cholagogue. 
 
Table 4 
Top 10 best-selling phytotherapics in 2014     
 
Phytotherapic/Laboratory Indication Plant specie- (DCB) 
1 – Seakalm (Natulab) 
 
Anxiolytic Passiflora incarnata 
2 – Abrilar (FQM) 
 
Expectorant Hedera helix L. 
3 – Tamarine (Farmasa) 
 
Laxative 
Senna alexandrina Mill. 
Cassia fistula 
Coriandrum sativum 
4 – Gerovital (EMS) Multivitamin Panax ginseng C. A. Mey. 
5 – Calman (Ativus) Anxiolytic 
Passiflora incarnata 
Salix alba 
Crataegus oxyacantha 
6 – Eparema (Takeda) 
 
Cholagogue 
Peumus boldus Molina 
Frangula purshiana (DC.) A. Gray 
Rheum palmatum L. 
7 – Pasalix (Marjan Farma) Anxiolytic 
Passiflora incarnata 
Salix alba 
Crataegus oxyacantha 
8 - Natus Gerin (Legrand) Multivitamin Panax ginseng C. A. Mey. 
9 – Maracugina (Hypermarcas) Anxiolytic 
Passiflora alata 
Erythrina mulungu 
Crataegus oxyacantha 
10 – Ginkomed (Cimed) 
 
Cerebral vasodilator Ginkgo biloba L. 
SOURCE: Adapted from IMS Health (2014) 
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The Brazilian scenario shows great growth 
potential in the herbal medicines market, and in 2014, 
approximately 56 million units were sold, totaling R$ 
1.1 billion, with growth of 6.1% sales in relation to 
the year 2013 (ANVISA, 2015).  
The herbal medicines market is growing at a 
slower pace than the pharmaceutical market in 
general, due to the increased investment in the 
development and launch of synthetic drugs. However, 
this market has expanded and gained interest in 
investment by several companies (Valécio, 2015). 
In view of the potential for growth, 
investments have been made in the development of 
herbal medicines. It also receives support from the 
Ministry of Health, which through public policies has 
improved and strengthened the use, research, and 
development of herbal medicines. 
Since much of the investment is made in the 
launching of products with synthetic origin, it is 
natural to have a slower growth in the herbal 
medicines market, compared to the pharmaceutical 
industry in general (Valécio, 2015). 
There is an increasing increase when one 
observes the billing in the category of phytotherapics 
marketed in Brazilian pharmacies. The increase in the 
financial sector similarly accompanies the increase in 
the number of publications on herbal products 
depending on the year. The industry's interest is 
linked to this growth, since, through research, new 
assets are sought for innovative purposes. As a result, 
we obtain a great variety of products that move the 
Brazilian market. 
Together, there is an increase in the popular 
interest in using less aggressive and legally 
recognized alternative therapies, being easily 
accessible to patients who attend the SUS, also 
contributes significantly to a greater consumption of 
these products both by the public network and by 
particular prescriptions. 
This reflects the triad alignment presented in 
this article, the records increasing as a result of the 
increase of researches and articles published in the 
area, linked to the financial interest of large industries 
in promoting the commercialization of these products 
in order to meet the needs of the population. 
The Brazilian industry believes in the growth 
potential of this segment and seeks to develop and 
launch new products, based on the vast biodiversity 
of our country, and the significant number of 
scientific publications on medicinal plants and herbal 
medicines, which has grown considerably over the 
years (Carvalho et al., 2011). Some reasons 
contribute to the development of the market, and the 
population's interest in herbal medicines, which are 
the patients' preference for natural therapies, the 
belief that natural medicines have fewer side effects, 
a tendency towards self-medication as a preventive 
treatment, and the lowest cost to consumers (Calixto, 
2001). 
 
Final considerations 
The use of medicinal plants is a field that is 
expanding in the world and in Brazil, a fact that can 
be attributed to the presence of a vast biome with 
great potential to be explored in a conscious way, to 
the growing use of phytotherapics by the population 
and to the development of research in this area. It is 
observed that many public policies and laws currently 
support and promote the rational use of these. 
In Brazil over the last two decades there has 
been an increase in research and publications in this 
field. On the rise is also the pharmaceutical industry 
in this segment that already makes more than 1 
billion reais in our country. 
In this way, the search for less aggressive 
therapies, contribute to the expansion of the number 
of consumers in this segment, which provides a good 
growth and commercial development of herbal 
medicines. 
Where the pharmaceutical industries that 
market herbal products go to a scenario where they 
develop strategies in order to invest in this line of 
innovative and sustainable products. 
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